On November 8, 2022 Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, reported that it will present new data at the 2022 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, being held in Boston, United States, between 8-12 November 2022 (Press release, Glycotope, NOV 8, 2022, View Source [SID1234623341]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: "We are looking forward to providing an update on the progress of our lead antibody program, GT-002, at SITC (Free SITC Whitepaper). The glycosylation-dependent binding of LYPD3 by GT-002 leads to markedly improved tumor-selectivity compared to protein binding antibodies resulting in reduced binding to healthy tissues. In addition, we will deliver a presentation on our GlycoTarget platform, showcasing how, by utilizing the same principle, our technology can be applied to significantly improve selectivity across other targets beside LYPD3."

About GT-002

Antibodies targeting LYPD3 (C4.4A) with increased tumor-specificity. LYPD3 is expressed in various cancer indications with high medical need, including squamous cell carcinoma of the head and neck (HNSCC). Upon binding to LYPD3, the antibody is effectively internalized. The improved tumor-specificity of GT-002 results in reduced binding to healthy-tissue expressed LYPD3 making it suitable for the development of highly potent therapies like ADCs, CARs or radio pharmaceutics.